Get notified when GENB files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — Management and the independent auditor have concluded there is substantial doubt about the company's ability to continue as a going concern.
  • Gb-0895 Pivotal Trial Design Risk (new) — The company proceeded directly to Phase 3 with a single dose of GB-0895 without conducting a dose-ranging trial, despite FDA and EMA recommendations, increasing the risk of trial failure.
  • Gb-0895 Device Transition Risk (new) — The company is transitioning GB-0895 from a syringe and vial to a pre-filled syringe/autoinjector for pivotal Phase 3 trials, which may require bridging studies or human factors testing and could delay approval.
  • Sole-source Reliance On Lonza and Wuxi (new) — The company depends on a single CDMO for each of two key product candidates, GB-0895 and GB-4362, creating supply chain risk.
NASDAQ: GENB Generate Biomedicines, Inc. 424B4

Generate Biomedicines prices $400M IPO at $16/share; net proceeds to fund Phase 3 asthma trials

Filed February 27, 2026 · ~2 min read

Key Changes

  • high

    Generate Biomedicines is offering 25,000,000 shares at $16.00 per share, raising $400 million gross before underwriting discounts and expenses.

    The Offering verify on EDGAR →
  • high

    Net proceeds to the company are estimated at $368.8 million (or $424.9 million if underwriters fully exercise their option to purchase additional shares).

    Use of Proceeds verify on EDGAR →
  • high

    The company plans to use approximately $300 million of net proceeds to advance GB-0895 through two Phase 3 trials in severe asthma.

    Use of Proceeds verify on EDGAR →

4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade GENB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify